These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9735970)

  • 1. Compliance with depot antipsychotic medication by patients attending outpatient clinics.
    Heyscue BE; Levin GM; Merrick JP
    Psychiatr Serv; 1998 Sep; 49(9):1232-4. PubMed ID: 9735970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen.
    Weiden P; Rapkin B; Zygmunt A; Mott T; Goldman D; Frances A
    Psychiatr Serv; 1995 Oct; 46(10):1049-54. PubMed ID: 8829787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Problems of compliance in the outpatient treatment of schizophrenia.
    Kane JM
    J Clin Psychiatry; 1983 Jun; 44(6 Pt 2):3-6. PubMed ID: 6133854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of splitting risperidone tablets on medication adherence and on clinical outcomes for patients with schizophrenia.
    Weissman EM; Dellenbaugh C
    Psychiatr Serv; 2007 Feb; 58(2):201-6. PubMed ID: 17287376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community treatment orders: relationship to clinical care, medication compliance, behavioural disturbance and readmission.
    Vaughan K; McConaghy N; Wolf C; Myhr C; Black T
    Aust N Z J Psychiatry; 2000 Oct; 34(5):801-8. PubMed ID: 11037366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia.
    Hong J; Novick D; Brugnoli R; Bertsch J; Haro JM
    Hum Psychopharmacol; 2013 Sep; 28(5):438-46. PubMed ID: 23775950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight.
    Garavan J; Browne S; Gervin M; Lane A; Larkin C; O'Callaghan E
    Compr Psychiatry; 1998; 39(4):215-9. PubMed ID: 9675506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
    Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
    J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Community treatment orders and antipsychotic long-acting injections.
    Lambert TJ; Singh BS; Patel MX
    Br J Psychiatry Suppl; 2009 Nov; 52():S57-62. PubMed ID: 19880919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
    Glazer WM; Ereshefsky L
    J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Depot antipsychotics in the year 2011].
    Knegtering H; Oolders H; Ruijsink MA; van der Moolen AE
    Tijdschr Psychiatr; 2011; 53(2):95-105. PubMed ID: 21319066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substance abuse and the management of medication nonadherence in schizophrenia.
    Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
    J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative symptoms of schizophrenia and compliance with medication.
    Tattan TM; Creed FH
    Schizophr Bull; 2001; 27(1):149-55. PubMed ID: 11215543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
    Stanković Z; Britvić D; Vuković O; Ille T
    Psychiatr Danub; 2008 Mar; 20(1):42-52. PubMed ID: 18376330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension.
    Piette JD; Heisler M; Ganoczy D; McCarthy JF; Valenstein M
    Psychiatr Serv; 2007 Feb; 58(2):207-12. PubMed ID: 17287377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of community treatment orders for treatment of schizophrenia with oral or depot antipsychotic medication: clinical outcomes.
    Muirhead D; Harvey C; Ingram G
    Aust N Z J Psychiatry; 2006; 40(6-7):596-605. PubMed ID: 16756586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose response of prophylactic antipsychotics.
    Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
    J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refill rate of antipsychotic drugs: an easy and inexpensive method to monitor patients' compliance by using computerised pharmacy data.
    Rijcken CA; Tobi H; Vergouwen AC; de Jong-van den Berg LT
    Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):365-70. PubMed ID: 15170765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.